Guilford Pharmaceuticals Announces Resignation of Andrew R. Jordan, Chief Financial Officer

Guilford Pharmaceuticals Announces Resignation of Andrew R.
Jordan, Chief Financial Officer 


BALTIMORE, May 3  /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. 
announced today that Andrew R. Jordan, Executive Vice President, Finance and
Administration and Chief Financial Officer, resigned from the Company,
effective May 31st, and has accepted a new position as Senior Vice President
and Chief Financial Officer with Odyssey Pharmaceuticals Inc.  Guilford has
commenced a search for a replacement.

Craig R. Smith, M.D., Chairman, President and Chief Executive Officer of
Guilford, commented, "Since joining Guilford in 1993, Andy has played a pivotal
role in shepherding the Company through a period of substantial growth.  He has
built a first-rate Finance and Accounting department and led us through
numerous transactions that have kept Guilford financially strong through the
years.  Everyone at Guilford owes Andy a debt of gratitude for his loyal and
devoted service to the Company."

"Making the decision to leave Guilford was very difficult," remarked Andrew
Jordan.  "I continue to believe in the Company's mission and have great
confidence in Guilford's future.  Guilford is poised for success both on the
commercial and clinical development fronts over the next several years.  I have
enjoyed working with the Guilford management team and all of the employees at
Guilford these past ten years.  The position I have accepted will offer me new
opportunities and challenges that are very appealing to me."

About Guilford

Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical company
engaged in the research, development and commercialization of products that
target the hospital market.  Presently, Guilford markets two commercial
products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the
treatment of brain cancer, and AGGRASTAT(R) Injection (tirofiban
hydrochloride), a glycoprotein GP IIb/IIIa receptor antagonist used for the
treatment of acute coronary syndrome (ACS).  Guilford's product pipeline
includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating
Parkinson's disease and post-prostatectomy erectile dysfunction.

CONTACT:  Stacey Jurchison, Director, Corporate Communications, Guilford
Pharmaceuticals, [phone]; . http://www.guilfordpharm.com/. 

DATASOURCE: Guilford Pharmaceuticals Inc.



CONTACT:  Stacey Jurchison, Director, Corporate Communications, Guilford

Pharmaceuticals, [phone], 



Web site:  http://www.guilfordpharm.com/ 



Company News On-Call:  http://www.prnewswire.com/comp/112882.html

Copyright